ProfileGDS4814 / ILMN_1737152
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 51% 39% 48% 59% 30% 11% 14% 25% 20% 16% 44% 33% 48% 38% 34% 18% 50% 29% 19% 53% 29% 18% 19% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)50.913651
GSM780708Untreated after 4 days (C2_1)47.463739
GSM780709Untreated after 4 days (C3_1)49.833648
GSM780719Untreated after 4 days (C1_2)54.914259
GSM780720Untreated after 4 days (C2_2)45.589730
GSM780721Untreated after 4 days (C3_2)41.570511
GSM780710Trastuzumab treated after 4 days (T1_1)42.294114
GSM780711Trastuzumab treated after 4 days (T2_1)44.640225
GSM780712Trastuzumab treated after 4 days (T3_1)43.53520
GSM780722Trastuzumab treated after 4 days (T1_2)42.677816
GSM780723Trastuzumab treated after 4 days (T2_2)48.802644
GSM780724Trastuzumab treated after 4 days (T3_2)46.305633
GSM780713Pertuzumab treated after 4 days (P1_1)49.977648
GSM780714Pertuzumab treated after 4 days (P2_1)47.18438
GSM780715Pertuzumab treated after 4 days (P3_1)46.379934
GSM780725Pertuzumab treated after 4 days (P1_2)43.167918
GSM780726Pertuzumab treated after 4 days (P2_2)50.564750
GSM780727Pertuzumab treated after 4 days (P3_2)45.384429
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)43.338519
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)51.770553
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)45.440129
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)43.128218
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)43.376519